Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Invasive Aspergillosis: later-stage trial registry
1 of 2 indexed Invasive Aspergillosis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Invasive Aspergillosis: 2 US clinical trials tracked, 1 recruiting.
Invasive Aspergillosis is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is F2G Biotech, running 1 of these trials.
Enrollment posture brief
Registry condition invasive-aspergillosis
OPEN 1 | RECR 50% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Invasive Aspergillosis lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Invasive Aspergillosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Invasive Aspergillosis is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01386437
Olorofim Aspergillus Infection Study
F2G Biotech
NCT05101187
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Invasive Aspergillosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Invasive Aspergillosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Invasive Aspergillosis page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Invasive Aspergillosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- F2G Biotech sponsors the most Invasive Aspergillosis trials on record, review their full trial history before evaluating a specific study. See F2G Biotech's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Invasive Aspergillosis condition card totals 2 registered trials; most-linked intervention AmBisome®; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.